Skip to main content
. Author manuscript; available in PMC: 2017 Apr 15.
Published in final edited form as: Clin Cancer Res. 2016 Apr 15;22(8):2083–2095. doi: 10.1158/1078-0432.CCR-15-2208

Figure 6. CD133+-cell-selective and NOTCH1-dependent SKP2 expression in ACC cells.

Figure 6

(A-C) SKP2 is selectively expressed in CD133+ Accx11 cells as demonstrated by qRT-PCR (A), immunoblot (B), and shows cytoplasmic localization in spheroid-forming CD133+ cells as demonstrated by IF (C). β-actin serves as a control for (A) and (B). (D-E) Inhibition of Notch signaling by siRNA (D) and DAPT (E) decreases expression of SKP2 in bulk Accx11 cells (qRT-PCR). (F) DAPT blocks expression of activated NOTCH1 (N1ICD) and its target SKP2 in CD133+ ACC cells and up-regulates p27Kip1, a SKP2 substrate. β-actin serves as a loading control.